Opus Genetics (NASDAQ:IRD – Get Free Report) and Verastem (NASDAQ:VSTM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.
Insider and Institutional Ownership
15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Opus Genetics and Verastem’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Opus Genetics | -892.36% | -338.88% | -191.21% |
| Verastem | -391.17% | -486.40% | -91.56% |
Volatility & Risk
Analyst Recommendations
This is a summary of recent recommendations and price targets for Opus Genetics and Verastem, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Opus Genetics | 2 | 0 | 12 | 1 | 2.80 |
| Verastem | 1 | 1 | 7 | 2 | 2.91 |
Opus Genetics presently has a consensus price target of $10.18, indicating a potential upside of 137.34%. Verastem has a consensus price target of $15.60, indicating a potential upside of 265.34%. Given Verastem’s stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than Opus Genetics.
Earnings and Valuation
This table compares Opus Genetics and Verastem”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Opus Genetics | $14.20 million | 24.59 | -$49.59 million | ($1.33) | -3.23 |
| Verastem | $30.91 million | 12.14 | -$209.47 million | ($2.70) | -1.58 |
Opus Genetics has higher earnings, but lower revenue than Verastem. Opus Genetics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Summary
Verastem beats Opus Genetics on 8 of the 15 factors compared between the two stocks.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
About Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
